Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 23, 2024, Eric Forman, the Vice President and Chief Operating Officer of Lixte Biotechnology Holdings, Inc. (the "Company") provided written notice to the Company of his resignation from such positions, effective as of December 31, 2024. Accordingly, the employment agreement between Mr. Forman and the Company dated July 15, 2020 and subsequently amended on August 12, 2020 and November 6, 2022 will terminate effective as of December 31, 2024.

Mr. Forman's resignation was for personal reasons and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.